Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

BACKGROUND: Hepatocellular carcinoma (HCC) is a common primary malignant tumor which usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a first line medicine for advanced stage HCC; however, it has been faced with enormous resistance. Simvastatin (Sim) is a choles...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jiao, Dai, Weiqi, Mao, Yuqing, Wu, Liwei, Li, Jingjing, Chen, Kan, Yu, Qiang, Kong, Rui, Li, Sainan, Zhang, Jie, Ji, Jie, Wu, Jianye, Mo, Wenhui, Xu, Xuanfu, Guo, Chuanyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993409/
https://www.ncbi.nlm.nih.gov/pubmed/32000827
http://dx.doi.org/10.1186/s13046-020-1528-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993409/
https://www.ncbi.nlm.nih.gov/pubmed/32000827
http://dx.doi.org/10.1186/s13046-020-1528-x

Ejemplares similares